Headquartered in Redwood City, CA Fiscal year ends December NASDAQ: JSPR jaspertx.com
Jasper Therapeutics is a clinical-stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. Following its July 2026 acquisition of Kira Pharmaceuticals, the combined company is advancing a pipeline of three clinical-stage assets: KP-104 (Vensobafusp alfa), a bifunctional biologic targeting both the alternative and terminal complement pathways for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and high unmet need nephrology disorders; briquilimab, an anti-KIT antibody with broad therapeutic utility across transplant and immunologic indications including conditioning for stem cell transplant and mast cell-mediated diseases such as chronic urticarias and allergic asthma; and KP-701, a dual-acting anti-CD79BxCD32B monoclonal antibody for autoantibody-mediated disorders. The company is pre-revenue and trades on Nasdaq under the ticker JSPR. Updated
Pre-Market Stock Futures: Futures are trading higher after President Trump signalled that talks with Iran are progressing positively, as we get ready to start another trading week, with the same issues that…
Jasper Therapeutics is a clinical-stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases.
The Wall Street consensus 12-month price target for JSPR is $20.00.
